StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Friday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

Shares of NASDAQ:TXMD opened at $1.46 on Friday. TherapeuticsMD has a 1 year low of $1.43 and a 1 year high of $3.07. The business’s 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.78.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million during the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative return on equity of 13.90%.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.